Literature DB >> 32687611

Quantifying immunoregulation by autoantigen-specific T-regulatory type 1 cells in mice with simultaneous hepatic and extra-hepatic autoimmune disorders.

Hassan Jamaleddine1, Pere Santamaria2,3, Anmar Khadra1.   

Abstract

Nanoparticles (NPs) displaying autoimmune disease-relevant peptide-major histocompatibility complex class II molecules (pMHCII-NPs) trigger cognate T-regulatory type 1 (Tr1)-cell formation and expansion, capable of reversing organ-specific autoimmune responses. These pMHCII-NPs that display epitopes from mitochondrial protein can blunt the progression of both autoimmune hepatitis (AIH) and experimental autoimmune encephalomyelitis (EAE) in mice carrying either disease. However, with co-morbid mice having both diseases, these pMHCII-NPs selectively treat AIH. In contrast, pMHCII-NPs displaying central nervous system (CNS)-specific epitopes can efficiently treat CNS autoimmunity, both in the absence and presence of AIH, without having any effects on the progression of the latter. Here, we develop a compartmentalized population model of T-cells in co-morbid mice to identify the mechanisms by which Tr1 cells mediate organ-specific immunoregulation. We perform time-series simulations and bifurcation analyses to study how varying physiological parameters, including local cognate antigenic load and rates of Tr1-cell recruitment and retention, affect T-cell allocation and Tr1-mediated immunoregulation. Various regimes of behaviour, including 'competitive autoimmunity' where pMHCII-NP-treatment fails against both diseases, are identified and compared with experimental observations. Our results reveal that a transient delay in Tr1-cell recruitment to the CNS, resulting from inflammation-dependent Tr1-cell allocation, accounts for the liver-centric effects of AIH-specific pMHCII-NPs in co-morbid mice as compared with mice exclusively having EAE. They also suggest that cognate autoantigen expression and local Tr1-cell retention are key determinants of effective regulatory-cell function. These results thus provide new insights into the rules that govern Tr1-cell recruitment and their autoregulatory function.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  Tr1-cell recruitment and retention; compartmental cell population model; nanomedicine; simultaneous autoimmune disorders; steady-state and transient dynamics

Mesh:

Substances:

Year:  2020        PMID: 32687611      PMCID: PMC7576881          DOI: 10.1111/imm.13241

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  33 in total

Review 1.  Sniffers, buzzers, toggles and blinkers: dynamics of regulatory and signaling pathways in the cell.

Authors:  John J Tyson; Katherine C Chen; Bela Novak
Journal:  Curr Opin Cell Biol       Date:  2003-04       Impact factor: 8.382

2.  The long and winding road to understanding and conquering type 1 diabetes.

Authors:  Pere Santamaria
Journal:  Immunity       Date:  2010-04-23       Impact factor: 31.745

3.  Autoimmunity: Antigen-specific immunotherapy.

Authors:  David Wraith
Journal:  Nature       Date:  2016-02-17       Impact factor: 49.962

4.  Modeling competition among autoreactive CD8+ T cells in autoimmune diabetes: implications for antigen-specific therapy.

Authors:  Athanasius F M Marée; Pere Santamaria; Leah Edelstein-Keshet
Journal:  Int Immunol       Date:  2006-05-25       Impact factor: 4.823

5.  Quantifying immunoregulation by autoantigen-specific T-regulatory type 1 cells in mice with simultaneous hepatic and extra-hepatic autoimmune disorders.

Authors:  Hassan Jamaleddine; Pere Santamaria; Anmar Khadra
Journal:  Immunology       Date:  2020-09-11       Impact factor: 7.397

6.  Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells.

Authors:  Nicola Gagliani; Chiara F Magnani; Samuel Huber; Monica E Gianolini; Mauro Pala; Paula Licona-Limon; Binggege Guo; De'Broski R Herbert; Alessandro Bulfone; Filippo Trentini; Clelia Di Serio; Rosa Bacchetta; Marco Andreani; Leonie Brockmann; Silvia Gregori; Richard A Flavell; Maria-Grazia Roncarolo
Journal:  Nat Med       Date:  2013-04-28       Impact factor: 53.440

7.  Ubiquitous antigen-specific T regulatory type 1 cells variably suppress hepatic and extrahepatic autoimmunity.

Authors:  Channakeshava Sokke Umeshappa; Jacques Mbongue; Santiswarup Singha; Saswat Mohapatra; Jun Yamanouchi; Justin A Lee; Roopa Hebbandi Nanjundappa; Kun Shao; Urs Christen; Yang Yang; Kristofor K Ellestad; Pere Santamaria
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 8.  Type 1 regulatory T cells (Tr1) in autoimmunity.

Authors:  Caroline Pot; Lionel Apetoh; Vijay K Kuchroo
Journal:  Semin Immunol       Date:  2011-08-12       Impact factor: 11.130

Review 9.  T-cell co-stimulatory pathways in autoimmunity.

Authors:  Jörg J Goronzy; Cornelia M Weyand
Journal:  Arthritis Res Ther       Date:  2008-10-15       Impact factor: 5.156

10.  Predictive models of type 1 diabetes progression: understanding T-cell cycles and their implications on autoantibody release.

Authors:  Majid Jaberi-Douraki; Massimo Pietropaolo; Anmar Khadra
Journal:  PLoS One       Date:  2014-04-04       Impact factor: 3.240

View more
  2 in total

1.  Quantifying immunoregulation by autoantigen-specific T-regulatory type 1 cells in mice with simultaneous hepatic and extra-hepatic autoimmune disorders.

Authors:  Hassan Jamaleddine; Pere Santamaria; Anmar Khadra
Journal:  Immunology       Date:  2020-09-11       Impact factor: 7.397

Review 2.  Peptide-MHC-Based Nanomedicines for the Treatment of Autoimmunity: Engineering, Mechanisms, and Diseases.

Authors:  Pau Serra; Pere Santamaria
Journal:  Front Immunol       Date:  2021-01-26       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.